Shares of Shire PLC traded down 0.70% during mid-day trading on Wednesday, hitting $86.37. Shire PLC has a one year low of $82.11 and a one year high of $108.79. The company has a market cap of $16.016 billion and a P/E ratio of 18.67.
Shire PLC last issued its quarterly earnings data on Thursday, April 26th. The company reported $1.24 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.52 by $0.72. Shire PLC’s revenue was up 20.6% compared to the same quarter last year. Analysts expect that Shire PLC will post $1.52 EPS next quarter.
A number of other analysts have also recently weighed in on SHPGY. Analysts at Goldman Sachs (NYSE: GS) reiterated a “conviction buy” rating on shares of Shire PLC in a research note to investors on Friday, May 25th. Separately, analysts at BNP Paribas (EPA: BNP) upgraded shares of Shire PLC from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, May 11st. Finally, analysts at Nomura (NYSE: NMR) initiated coverage on shares of Shire PLC in a research note to investors on Wednesday, April 4th. They set a “buy” rating on the stock.
Shire plc (Shire) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.